|apixaban package insert||0.82||0.3||5182||38|
|apixaban package insert fda||0.9||0.9||8196||26|
|apixaban package insert pdf||0.87||0.2||7891||60|
|apixaban package insert 2019||0.76||0.4||5670||4|
|apixaban package insert dosing||1.66||0.8||998||10|
|apixaban package insert update||0.09||0.2||5898||48|
|apixaban package insert citation||1.8||0.7||9046||2|
|apixaban package insert g tube||0.65||0.9||3116||9|
|package insert of apixaban||1.13||1||7325||29|
Combined P-gp and Strong CYP3A4 Inhibitors: Inhibitors of P-glycoprotein (P-gp) and cytochrome P450 3A4 (CYP3A4) increase exposure to apixaban and increase the risk of bleeding.Does apixaban (Eliquis) have anti-FXa activity?
ELIQUIS (apixaban) Product Monograph Page 9 of 79 Apixaban demonstrates anti-FXa activity as evident by reduction in Factor-Xa enzyme activity in the Rotachrom® Heparin Anti-Xa assay data from clinical studies.How much Apixaban can you take in a day?
In controlled clinical trials, orally administered apixaban in healthy subjects at doses up to 50 mg daily for 3 to 7 days (25 mg twice-daily for 7 days or 50 mg once-daily for 3 days) had no clinically relevant adverse effects.